The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
Former DCGI and now advisor to UP CM highlights medical device growth, healthcare expansion, and investment opportunities in the state
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
Designed for high-throughput genomic analysis, the laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Subscribe To Our Newsletter & Stay Updated
